Related to University of Oxford to Sequence Whole Genomes of 500 People Using Illumina Technology

• Sequencing in the Dark
  Analysis of Life Technologies’ Ion Torrent sequencing platform points to significance of photon-free technology.
  
• Enzo Sues Roche, Gen-Probe, and Life Technologies in Patent Infringement Case
  Patent under dispute expires in 2023, and defendants plan on fighting the lawsuit.
  
• Roche, Illumina Duke It Out in Potential $5.7B Takeover Deal
  Roche’s hostile $44.50 per share bid could also spark additional sequencing acquisition wars.
  
• U.K. Groups Grapple with Ethical Issues Linked to Clinical Sequencing
  Questions cover data dissemination, bioinformatics, and more education.
  
• Myriad, Prometheus Continue to Defend Diagnostic Patents while Others Urge More Licensing
  Battle raged on at second USPTO hearing tasked with evaluating the impact of patents on the availability of confirmatory tests.
  
• Lawyers Offer Predictions for Myriad, Diagnostic Field Based on Supreme Court’s Decision Against Prometheus
  Advice focuses on ensuring transformative steps are included in claims.
  
• This Time Last Year: Diagnostic Deals, mAb Therapeutics, and Obesity Drug Development
  Among big news was Roche’s companion diagnostic alliance with Clovis, a melanoma deal with BMS, and FDA’s Avastin decision.
  
• With USPTO Report Near, Comments Reflect Confirmatory Diagnostic Testing Divide
  Dx makers would like to keep patent protection, but patient groups say it stifles broader access to genetic tests at lower cost.
  
• LAVAgel for Protein Diagnostics
  Researchers introduce a microfluidic, single-channel, multistage immunoblotting strategy toward scalable protein isoform analysis.
  
• Genome Testing Reduces Overtreatment
  Study after study has shown that molecular diagnostics can help oncologists more effectively treat patients.
  
• 7 Biotech Trends for the Coming Year
  What does 2013 hold for the industry?
  
• 10 Predictions That Will Transform Healthcare
  Peer into GEN's crystal ball for a glimpse of what's to come.
  
• Detecting Acquired Drug Resistance in Cancer
  New methods allow noninvasive analysis in blood plasma.
  
• Your Genes, Your Choice?
  Critics say the American College of Medical Genetics and Genomics’ recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy.
  
• R&D Direction in 2012 for Sequencing Technologies Is Aimed at Clinical Medicine
  Companies are focused on making these platforms smaller and easier to use.
  
• Standardization Key to Taking Next-Generation Sequencing to the Next Level
  As NGS technology makes steady progress with faster and cheaper machines, regulation will have to keep up.
  
• Sequencing Firms Set Up Centers to Advance Genomics Research and Instrument Sales
  Strategy provides a feedback loop to improve instrumentation and develop new applications.
  
• Will Roche Really Drop Illumina and Seek out Another Sequencing Firm?
  Oxford Nanopore and PacBio both have exciting technologies, but Illumina remains market leader.
  
• Illumina, Complete Genomics Prepare for Legal Battle over Sequencing IP
  Illumina filed the case stating that the Complete Genomics Analysis Platform infringes on three of its patents.
  
• Moving Genomics Closer to the Clinic
  Foundation Medicine and Memorial Sloan-Kettering Cancer Center are working to translate genomic information into personalized cancer treatment.